Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

por McClung, M. R., Balske, A., Burgio, D. E., Wenderoth, D., Recker, R. R.
Publicado 2012

Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients

por Misof, B.M., Blouin, S., Lueger, S., Paschalis, E.P., Recker, R.R., Phipps, R., Klaushofer, K., Roschger, P.
Publicado 2017

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

por McClung, M. R., Miller, P. D., Brown, J. P., Zanchetta, J., Bolognese, M. A., Benhamou, C. L., Balske, A., Burgio, D. E., Sarley, J., McCullough, L. K., Recker, R. R.
Publicado 2011